Spot Biosystems emerges from stealth with $40M raised, reporting early human data showing dystrophin restoration in two children with Duchenne muscular dystrophy.
A startup with operations in California and China has quietly begun tests of a genetic medicine that could restore dystrophin, the vital muscle protein that …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Regenxbio said Thursday that its Duchenne muscular dystrophy gene therapy met the bar in a pivotal study, and it’s aiming for FDA…
Latus Bio raised $42 million as it prepares to seek FDA approval to start a clinical trial for its gene therapy for Huntington's…
Though two serious side effects muddied the results, CEO Curran Simpson expressed optimism about a clearance and claimed FDA…
Regenxbio said its experimental gene therapy for Duchenne muscular dystrophy succeeded in a trial, paving the way for a…
Servier will pick up the muscular dystrophy business from Edgewise Therapeutics, giving the French pharma company access to an…
New York City-based startup Waypoint Bio has raised $20 million in series A financing to test multiple cell therapies in China.
